My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 150

    1.

    Short-term intraocular pressure trends following intravitreal injections of ranibizumab (Lucentis) for the treatment of wet age-related macular degeneration.

    Mojica G, Hariprasad SM, Jager RD, Mieler WF.

    Br J Ophthalmol. 2008 Apr;92(4):584. No abstract available. PMID: 18369083 [PubMed - indexed for MEDLINE]Related articles

    2.

    Short-term effect of intravitreal anti-VEGFs delivery on intraocular pressure.

    Nabili S, Stevenson M, Chakravarty U, Moutray T.

    Br J Ophthalmol. 2009 Apr;93(4):552-3. No abstract available. PMID: 19321481 [PubMed - indexed for MEDLINE]Related articles

    3.

    [VEGF in age-related macular degeneration. Part II. VEGF inhibitors use in age-related macular degeneration treatment]

    Wylegała E, Teper SJ.

    Klin Oczna. 2007;109(1-3):97-100. Review. Polish. PMID: 17687925 [PubMed - indexed for MEDLINE]Related articles

    4.

    Re: Changes of intraocular pressure after intravitreal injection of bevacizumab (Avastin).

    Utman SA, Dhillon B.

    Retina. 2008 Apr;28(4):667; author reply 667-8. No abstract available. PMID: 18398378 [PubMed - indexed for MEDLINE]Related articles

    5.

    Ranibizumab for neovascular age-related macular degeneration.

    Hernandez-Pastor LJ, Ortega A, Garcia-Layana A, Giraldez J.

    Am J Health Syst Pharm. 2008 Oct 1;65(19):1805-14. Review.PMID: 18796421 [PubMed - indexed for MEDLINE]Related articles

    6.

    [Lucentis versus Avastin--is there a light at the end of the tunnel for age-related macular degeneration patients?]

    Waisbourd M, Leibovitch I, Loewenstein A, Yassur Y.

    Harefuah. 2008 Jul;147(7):605-6, 662. Hebrew. PMID: 18814519 [PubMed - indexed for MEDLINE]Related articles

    7.

    Short-term intraocular pressure trends following intravitreal pegaptanib (Macugen) injection.

    Hariprasad SM, Shah GK, Blinder KJ.

    Am J Ophthalmol. 2006 Jan;141(1):200-1.PMID: 16387003 [PubMed - indexed for MEDLINE]Related articles

    8.

    [Angiogenesis inhibitors for vision loss. Ranibizumab for macular degeneration]

    Mohr-Andrä M, Mohr K.

    Pharm Unserer Zeit. 2007;36(6):437-40. Review. German. PMID: 17957687 [PubMed - indexed for MEDLINE]Related articles

    9.

    [The results of wet AMD treatment by intravitreal injections--preliminary report]

    Okruszko A, Borucka AI, Ulińska M, Szaflik J.

    Klin Oczna. 2007;109(10-12):389-93. Polish. PMID: 18488380 [PubMed - indexed for MEDLINE]Related articles

    10.

    [Ranibizumab for treatment of exudative age-related macular degeneration--own experience]

    Wykrota H, Gierek-Lapińska A, Trzciakowski K, Gajdzik-Gajdecka U.

    Klin Oczna. 2007;109(10-12):402-9. Polish. PMID: 18488382 [PubMed - indexed for MEDLINE]Related articles

    11.

    Treatment of neovascular age-related macular degeneration with intravitreal bevacizumab: efficacy of three consecutive monthly injections.

    Melamud A, Stinnett S, Fekrat S.

    Am J Ophthalmol. 2008 Jul;146(1):91-5. Epub 2008 May 2.PMID: 18455144 [PubMed - indexed for MEDLINE]Related articles

    12.

    Persisent ocular hypertension following intravitreal ranibizumab.

    Bakri SJ, McCannel CA, Edwards AO, Moshfeghi DM.

    Graefes Arch Clin Exp Ophthalmol. 2008 Jul;246(7):955-8. Epub 2008 Apr 19.PMID: 18425523 [PubMed - indexed for MEDLINE]Related articles

    13.

    Paracentesis before intravitreal injection of bevacizumab.

    Tsui YP, Chiang CC, Tsai YY.

    Can J Ophthalmol. 2008 Apr;43(2):239; author reply 239-40. No abstract available. PMID: 18347632 [PubMed - indexed for MEDLINE]Related articlesFree article

    14.

    Treatment of neovascular age-related macular degeneration with pegaptanib and boosting with bevacizumab or ranibizumab as needed.

    Farah SE.

    Ophthalmic Surg Lasers Imaging. 2008 Jul-Aug;39(4):294-8.PMID: 18717434 [PubMed - indexed for MEDLINE]Related articles

    15.

    [New drugs; pegaptanib and ranibizumab]

    van Bronswijk H, Dubois EA, van Meurs JC, Cohen AF.

    Ned Tijdschr Geneeskd. 2008 Jan 12;152(2):82-4. Review. Dutch. PMID: 18265796 [PubMed - indexed for MEDLINE]Related articles

    16.

    The price of sight--ranibizumab, bevacizumab, and the treatment of macular degeneration.

    Steinbrook R.

    N Engl J Med. 2006 Oct 5;355(14):1409-12. No abstract available. PMID: 17021315 [PubMed - indexed for MEDLINE]Related articles

    17.

    New treatments for age-related macular degeneration.

    Avery RL.

    Lancet. 2007 Oct 27;370(9597):1479-80; author reply 1480. No abstract available. PMID: 17964341 [PubMed - indexed for MEDLINE]Related articles

    18.

    Ranibizumab.

    Blick SK, Keating GM, Wagstaff AJ.

    Drugs. 2007;67(8):1199-206; discussion 1207-9. Review.PMID: 17521219 [PubMed - indexed for MEDLINE]Related articles

    19.

    Does intravitreal injection of bevacizumab have an effect on the blood-aqueus barrier function?

    Ziemssen F, Warga M, Neuhann IM, Leitritz M, Biester S, Grisanti S, Bartz-Schmidt KU.

    Br J Ophthalmol. 2006 Jul;90(7):922. No abstract available. PMID: 16782958 [PubMed - indexed for MEDLINE]Related articlesFree article

    20.

    Intravitreal ranibizumab and bevacizumab: a review of risk.

    Dafer RM, Schneck M, Friberg TR, Jay WM.

    Semin Ophthalmol. 2007 Jul-Sep;22(3):201-4. Review.PMID: 17763246 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity